{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(4)"],"submitter":["Richardson PG"],"pubmed_abstract":["Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months; <i>n</i> = 424) versus late responders (best confirmed response >4 months; <i>n</i> = 281). Newly diagnosed patients enrolled in TOURMALINE-MM2 receiving ixazomib-lenalidomide-dexamethasone (IRd) (<i>n</i> = 351) or placebo-Rd (<i>n</i> = 354) were evaluated <i>post hoc</i>. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months)"],"journal":["EJHaem"],"pagination":["995-1005"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10660432"],"repository":["biostudies-literature"],"pubmed_title":["Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial."],"pmcid":["PMC10660432"],"pubmed_authors":["Karlin L","Twumasi-Ankrah P","Voog E","Rajkumar SV","Yoon SS","Bahlis NJ","Rifkin RM","Suzuki K","Moreau P","Venner CP","Lonial S","Benboubker L","Offner F","Shibayama H","Richardson PG","Zhang X","Kumar SK","White D","Facon T","Villarreal M","Labotka R"],"additional_accession":[]},"is_claimable":false,"name":"Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.","description":"Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months; <i>n</i> = 424) versus late responders (best confirmed response >4 months; <i>n</i> = 281). Newly diagnosed patients enrolled in TOURMALINE-MM2 receiving ixazomib-lenalidomide-dexamethasone (IRd) (<i>n</i> = 351) or placebo-Rd (<i>n</i> = 354) were evaluated <i>post hoc</i>. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months)","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-07-14T20:01:42.462Z","creation":"2025-02-19T04:25:55.365Z"},"accession":"S-EPMC10660432","cross_references":{"pubmed":["38024593"],"doi":["10.1002/jha2.759"]}}